A Study to Assess the Safety and Tolerability of Lucerastat in Subjects With Fabry Disease

NCT02930655 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

14

Enrollment

INDUSTRY

Sponsor class

Conditions

Fabry Disease

Interventions

DRUG: Lucerastat
DRUG: Enzyme replacement therapy (ERT)

Sponsor

Idorsia Pharmaceuticals Ltd.